AMPA Receptor Antagonists as Potential Anticonvulsant Drugs (original) (raw)

Abstract

Over the last years α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors (AMPARs) have been intensively studied owing to their crucial role in physiological and pathological processes. Efforts targeting AMPAR have been focused on identification of ligands as potential therapeutic agents useful in the prevention and treatment of a variety of neurological and non-neurological diseases. In particular, extensive work was addressed to the discovery of selective antagonists some of which proved to be potent anticonvulsant agents.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (120)

  1. Walker, M. C.; Sander, J. W. New antiepileptic drug trials in developing countries: are they necessary? Seizure 1996, 5, 165-169.
  2. Bourgeois, B. F. New antiepileptic drugs. Arch. Neurol. 1998, 55 , 1181-1183.
  3. De Sarro, G.; Di Paola, E. D.; Gareri, P.; Gallelli, L.; Scotto, G.; De Sarro, A. Effects of some AMPA receptor antagonists on the development of tolerance in epilepsy-prone rats and in pentylenetetrazole kindled rats. Eur. J. Pharmacol. 1999, 368, 149- 159.
  4. Meldrum, B. Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs. Epilepsy Res. 2002, 50 , 33- 40.
  5. Chapman, A. G.; Hart, G. P. Anticonvulsant drug action and regional neurotransmitter amino acid changes. J. Neural. Transm. 1988, 72, 201-212.
  6. Meldrum, B. S.; Chapman, A. G. Excitatory amino acid receptors and antiepileptic drug development. Adv. Neurol. 1999, 79, 965- 978.
  7. Dingledine, R.; Borges, K.; Bowie, D.; Traynelis, S. F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51, 7-61.
  8. Sugiyama, H.; Ito, I.; Hirono, C. A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 1987, 325, 531- 533.
  9. Sladeczek, F.; Pin, J. P.; Recasens, M.; Bockaert, J.; Weiss, S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 1985, 317, 717-719.
  10. Tanabe, Y.; Masu, M.; Ishii, T.; Shigemoto, R.; Nakanishi, S. A family of metabotropic glutamate receptors. Neuron 1992, 8 , 169- 179.
  11. Houamed, K. M.; Kuijper, J. L.; Gilbert, T. L.; Haldeman, B. A.; O'Hara, P. J.; Mulvihill, E. R.; Almers, W.; Hagen, F. S. Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science 1991, 252, 1318-1321.
  12. Jingami, H.; Nakanishi, S.; Morikawa, K. Structure of the metabotropic glutamate receptor. Curr. Opin. Neurobiol. 2003, 13, 271-278.
  13. Stensbol, T. B.; Madsen, U.; Krogsgaard-Larsen, P. The AMPA receptor binding site: focus on agonists and competitive antagonists. Curr. Pharm. Des. 2002, 8, 857-872.
  14. Rosenmund, C.; Stern-Bach, Y.; Stevens, C. F. The tetrameric structure of a glutamate receptor channel. Science 1998, 280, 1596- 1599.
  15. Sutcliffe, M. J.; Wo, Z. G.; Oswald, R. E. Three-dimensional models of non-NMDA glutamate receptors. Biophys. J. 1996, 70, 1575-1589.
  16. Sutcliffe, M. J.; Smeeton, A. H.; Wo, Z. G.; Oswald, R. E. Three- dimensional models of glutamate receptors. Biochem. Soc. Trans 1998, 26, 450-458.
  17. Armstrong, N.; Gouaux, E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron 2000, 28, 165- 181.
  18. De Luca, L.; Macchiarulo, A.; Costantino, G.; Barreca, M. L.; Gitto, R.; Chimirri, A.; Pellicciari, R. Binding modes of noncompetitive AMPA antagonists: a computational approach. Farmaco 2003, 58, 107-113.
  19. Chenard, B. L.; Menniti, F. S. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. 1999, 5, 381-404.
  20. Chimirri, A.; Gitto, R.; Zappala, M. AMPA receptor antagonists. Exp. Opin. Ther. Patents 1999, 9, 557-570.
  21. Nikam, S. S.; Kornberg, B. E. AMPA receptor antagonists. Curr. Med. Chem. 2001, 8, 155-170.
  22. Hogner, A.; Greenwood, J. R.; Liljefors, T.; Lunn, M. L.; Egebjerg, J.; Larsen, I. K.; Gouaux, E.; Kastrup, J. S. Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX. J. Med. Chem. 2003, 46, 214-221.
  23. Kornberg, B. E.; Nikam, S. S. Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. United States Patent 6,096,744 2000.
  24. Auberson, Y. P. Competitive AMPA antagonism: a novel mechanism for antiepileptic drugs? Drugs of the Future 2001, 26 , 463-471.
  25. Bigge, C. F.; Malone, T. C.; Schelkun, R. M.; Yi, C. S. Glutamate (ampa/kainate) receptor antagonists: N-substituted fused azacycloalkylquinoxalinediones. Pfizer Inc. US 6057313 2000.
  26. Cordi, A. A.; Desos, P.; Randle, J. C.; Lepagnol, J. Structure- activity relationships in a series of 3-sulfonylamino-2-(1H)- quinolones, as new AMPA/kainate and glycine antagonists. Bioorg. Med. Chem. 1995, 3, 129-141.
  27. Cordi, A. A.; Desos, P.; Ruano, E.; Al-Badri, H.; Fugier, C.; Chapman, A. G.; Meldrum, B. S.; Thomas, J. Y.; Roger, A.; Lestage, P. Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity. Farmaco 2002, 57, 787-802.
  28. Mignani, S.; Bohme, G. A.; Boireau, A.; Cheve, M.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Stutzmann, J. M. 8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2- a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 591-596.
  29. Stutzmann, J. M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Mignani, S. 4,10- Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2- carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg. Med. Chem. Lett. 2000, 10, 1133-1137.
  30. Jimonet, P.; Cheve, M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Imperato, A.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. 8-Methylureido-10-amino-10-methyl-imidazo[1,2- a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists. Bioorg. Med. Chem. 2000, 8, 2211- 2217.
  31. Pratt, J.; Jimonet, P.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2- e]pyrazin-8-and -9-carboxylic (acetic) acid AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 2749-2754.
  32. Jimonet, P.; Bohme, G. A.; Bouquerel, J.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Hardy, J. C.; Hubert, P.; Manfre, F.; Nemecek, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Stutzmann, J. M.; Vuilhorgne, M.; Mignani, S. Bioisosteres of 9- carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2- carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action. Bioorg. Med. Chem. Lett. 2001, 11, 127-132.
  33. Stutzmann, J. M.; Bohme, G. A.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Jimonet, P.; Pratt, J.; Randle, J. C.; Ribeill, Y.; Vuilhorgne, M.; Mignani, S. Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted- imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 2001, 11, 1205-1210.
  34. Mignani, S.; Bohme, G. A.; Birraux, G.; Boireau, A.; Jimonet, P.; Damour, D.; Genevois-Borella, A.; Debono, M. W.; Pratt, J.; Vuilhorgne, M.; Wahl, F.; Stutzmann, J. M. 9-Carboxymethyl- 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocyl ic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg. Med. Chem. 2002, 10, 1627-1637.
  35. Solyom, S. Research on new AMPA antagonists of 2,3- benzodiazepine type. Pharmazie 2001, 56 Suppl. 1, S62-66.
  36. Donevan, S. D.; Rogawski, M. A. GYKI 52466, a 2,3- benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993, 10, 51-59.
  37. Szabados, T.; Gigler, G.; Gacsalyi, I.; Gyertyan, I.; Levay, G. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res. Bull. 2001, 55, 387-391.
  38. Donevan, S. D.; Yamaguchi, S.; Rogawski, M. A. Non-N-methyl- D-aspartate receptor antagonism by 3-N-substituted 2,3- benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther. 1994, 271, 25-29.
  39. Ruel, J.; Guitton, M. J.; Puell, J. L. Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist. CNS Drug Rev. 2002, 8, 235-254.
  40. Vilagi, I.; Takacs, J.; Gulyas-Kovacs, A.; Banczerowski-Pelyhe, I.; Tarnawa, I. Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. Brain Res. Bull. 2002, 59, 35-40.
  41. Andrási, F. Talampanel. Antiepileptic, Neuroprotectant, Skeletal muscle relaxant. Drugs of the Future 2001, 26, 754-756.
  42. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001, 43, 11-58.
  43. Hamori, T.; Solyom, S.; Berzsenyi, P.; Andrasi, F.; Tarnawa, I. Structural analogues of some highly active non-competitive AMPA antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 899-902.
  44. Gitto, R.; Zappalà, M.; De Sarro, G.; Chimirri, A. Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists. Farmaco 2002, 57, 129-134.
  45. Abraham, G.; Solyom, S.; Csuzdi, E.; Berzsenyi, P.; Ling, I.; Tarnawa, I.; Hamori, T.; Pallagi, I.; Horvath, K.; Andrasi, F.; Kapus, G.; Harsing, L. G., Jr.; Kiraly, I.; Patthy, M.; Horvath, G. New non competitive AMPA antagonists. Bioorg. Med. Chem. 2000, 8, 2127-2143.
  46. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappala, M.; Giusti, P.; Libri, V.; Constanti, A.; Chapman, A. G. 1-Aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: novel AMPA receptor antagonists. J. Med. Chem. 1997, 40, 1258- 1269.
  47. Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Quartarone, S.; Zappala, M.; Constanti, A.; Libri, V. 3,5-Dihydro-4H-2,3- benzodiazepine-4-thiones: a new class of AMPA receptor antagonists. J. Med. Chem. 1998, 41, 3409-3416.
  48. De Sarro, G.; Ferreri, G.; Gareri, P.; Russo, E.; De Sarro, A.; Gitto, R.; Chimirri, A. Comparative anticonvulsant activity of some 2,3- benzodiazepine derivatives in rodents. Pharmacol. Biochem. Behav. 2003, 74, 595-602.
  49. De Sarro, G.; Rizzo, M.; Sinopoli, V. A.; Gitto, R.; De Sarro, A.; Zappala, M.; Chimirri, A. Relationship between anticonvulsant activity and plasma level of some 2,3-benzodiazepines in genetically epilepsy-prone rats. Pharmacol .Biochem. Behav. 1998, 61, 215-220.
  50. De Sarro, G.; Rizzo, M.; Spagnolo, C.; Gitto, R.; De Sarro, A.; Scotto, G.; Zappala, M.; Chimirri, A. Anticonvulsant activity and plasma level of 2,3-benzodiazepin-4-ones (CFMs) in genetically epilepsy-prone rats. Pharmacol. Biochem. Behav. 1999, 63, 621- 627.
  51. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists. J. Med. Chem. 1999, 42, 4414-4421.
  52. De Sarro, A.; De Sarro, G.; Gitto, R.; Grasso, S.; Micale, N.; Quartarone, S.; Zappala, M. 7,8-Methylenedioxy-4H-2,3- benzodiazepin-4-ones as novel AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 971-976.
  53. De Sarro, G.; Chimirri, A.; De Sarro, A.; Gitto, R.; Grasso, S.; Giusti, P.; Chapman, A. G. GYKI 52466 and related 2,3- benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur J. Pharmacol. 1995, 294, 411-422.
  54. Bevacqua, F.; Basso, A.; Gitto, R.; Bradley, M.; Chimirri, A. Solid- phase Friedel-Crafts acylation on polystyrene resins-synthesis of antiepiletic 1-aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones.
  55. Tetrahedron Letters 2001, 42, 7683-7685.
  56. Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimirri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H- [1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. 2000, 43, 4834-4839.
  57. Chimirri, A.; Gitto, R.; Quartarone, S.; Orlando, V.; De Sarro, A.; De Sarro, G. B. Synthesis and pharmacological properties of new 3- ethoxycarbonyl-11H-[1,2,4]triazolo[4,5-c][2,3]benzodiazepines. Farmaco 2002, 57, 759-763.
  58. Gitto, R.; Orlando, V.; Quartarone, S.; De Sarro, G.; De Sarro, A.; Russo, E.; Ferreri, G.; Chimirri, A. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives. J. Med. Chem. 2003, 46, 3758-3761.
  59. Pelletier, J. C.; Hesson, D. P.; Jones, K. A.; Costa, A. M. Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem. 1996, 39, 343-346.
  60. Pei, X. F.; Sturgess, M. A.; Valenzuela, C. F.; Maccecchini, M. L. Allosteric modulators of the AMPA receptor: novel 6-substituted dihydrophthalazines. Bioorg. Med. Chem. Lett. 1999, 9, 539-542.
  61. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Zappala, M.; Puja, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)- ones. J. Med. Chem. 2000, 43, 2851-2859.
  62. Gitto, R.; Chimirri, A.; Zappala, M.; De Sarro, G.; De Sarro, A. Synthesis and pharmacological evaluation of 4-aryl-6,7- dimethoxyphthalazines as anticonvulsant agents. Medicinal Chemistry Research 2000, 10, 1-10.
  63. Li, B. Q.; Pei, X. F.; Maccecchini, M. Novel sulfur containing dihydrophthalazine antagonists of AMPA receptors. Washington DC, USA. 220th ACS Meeting 2000, MEDI 212.
  64. Chenard, B. L.; Welch, W. M.; Blake, J. F.; Butler, T. W.; Reinhold, A.; Ewing, F. E.; Menniti, F. S.; Pagnozzi, M. J. Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor antagonists: structure- activity relationship of the C-2 side chain tether. J. Med. Chem. 2001, 44, 1710-1717.
  65. Chenard, B. L.; Menniti, F. S.; Pagnozzi, M. J.; Shenk, K. D.; Ewing, F. E.; Welch, W. M. Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 1203-1205.
  66. Menniti, F. S.; Buchan, A. M.; Chenard, B. L.; Critchett, D. J.; Ganong, A. H.; Guanowsky, V.; Seymour, P. A.; Welch, W. M. CP- 465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 2003, 34, 171-176.
  67. Lazzaro, J. T.; Paternain, A. V.; Lerma, J.; Chenard, B. L.; Ewing, F. E.; Huang, J.; Welch, W. M.; Ganong, A. H.; Menniti, F. S. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 2002, 42, 143-153.
  68. Welch, W. M.; Ewing, F. E.; Huang, J.; Menniti, F. S.; Pagnozzi, M. J.; Kelly, K.; Seymour, P. A.; Guanowsky, V.; Guhan, S.; Guinn, M. R.; Critchett, D.; Lazzaro, J.; Ganong, A. H.; DeVries, K. M.; Staigers, T. L.; Chenard, B. L. Atropisomeric quinazolin-4- one derivatives are potent noncompetitive alpha-amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 177-181.
  69. Menniti, F. S.; Chenard, B. L.; Collins, M. B.; Ducat, M. F.; Elliott, M. L.; Ewing, F. E.; Huang, J. I.; Kelly, K. A.; Lazzaro, J. T.; Pagnozzi, M. J.; Weeks, J. L.; Welch, W. M.; White, W. F. Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor antagonists. Mol. Pharmacol. 2000, 58, 1310-1317.
  70. Yamashita, H.; Ohno, K.; Amada, Y.; Hattori, H.; Ozawa-Funatsu, Y.; Toya, T.; Inami, H.; Shishikura, J.; Sakamoto, S.; Okada, M.; Yamaguchi, T. Effects of 2-[N-(4-chlorophenyl)-N-methylamino]- 4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an orally active alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J. Pharmacol. Exp. Ther. 2004, 308, 127-133.
  71. Yamashita, H.; Ohno, K.; Inami, H.; Shishikura, J.; Sakamoto, S.; Okada, M.; Yamaguchi, T. Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy. Eur. J. Pharmacol. 2004, 494, 147-154.
  72. Weiser, T.; Brenner, M.; Palluk, R.; Bechtel, W. D.; Ceci, A.; Brambilla, A.; Ensinger, H. A.; Sagrada, A.; Wienrich, M. BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. J. Pharmacol. Exp. Ther. 1999, 289, 1343-1349.
  73. Feigin, V. Irampanel Boehringer Ingelheim. Curr. Opin. Investig. Drugs 2002, 3, 908-910.
  74. Weiser, T.; Wienrich, M.; Brenner, M.; Kubiak, R.; Weckesser, G.; Palluk, R. The AMPA receptor/Na(+) channel blocker BIIR 561 CL is protective in a model of global cerebral ischaemia. Eur. J. Pharmacol. 2001, 421, 165-170.
  75. Gitto, R.; Barreca, M. L.; De Luca, L.; De Sarro, G.; Ferreri, G.; Quartarone, S.; Russo, E.; Constanti, A.; Chimirri, A. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist. J. Med. Chem. 2003, 46, 197-200.
  76. Gitto, R.; Caruso, R.; Orlando, V.; Quartarone, S.; Barreca, M. L.; Ferreri, G.; Russo, E.; De Sarro, G.; Chimirri, A. Synthesis and anticonvulsant properties of tetrahydroisoquinoline derivatives. Farmaco 2004, 59, 7-12.
  77. Ferreri, G.; Chimirri, A.; Russo, E.; Gitto, R.; Gareri, P.; De Sarro, A.; De Sarro, G. Comparative anticonvulsant activity of N-acetyl-1- aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents. Pharmacol. Biochem. Behav. 2004, 77, 85-94.
  78. Barreca, M. L.; Gitto, R.; Quartarone, S.; De Luca, L.; De Sarro, G.; Chimirri, A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J. Chem. Inf. Comput. Sci. 2003, 43, 651-655.
  79. Macchiarulo, A.; De Luca, L.; Costantino, G.; Barreca, M. L.; Gitto, R.; Pellicciari, R.; Chimirri, A. QSAR study of anticonvulsant negative allosteric modulators of the AMPA receptor. J. Med. Chem. 2004, 47, 1860-1863.
  80. Bisaga, A.; Krzascik, P.; Jankowska, E.; Palejko, W.; Kostowski, W.; Danysz, W. Effect of glutamate receptor antagonists on N- methyl-D-aspartate-and (S)-alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid-induced convulsant effects in mice and rats. Eur. J. Pharmacol. 1993, 242, 213-220.
  81. Chapman, A. G.; Smith, S. E.; Meldrum, B. S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 1991, 9, 92-96.
  82. Durmuller, N.; Craggs, M.; Meldrum, B. S. The effect of the non- NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 1994, 17, 167-174.
  83. Lallement, G.; Pernot-Marino, I.; Foquin-Tarricone, A.; Baubichon, D.; Piras, A.; Blanchet, G.; Carpentier, P. Antiepileptic effects of NBQX against soman-induced seizures. Neuroreport 1994, 5, 425- 428.
  84. Loscher, W.; Honack, D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 1994, 259, R3-5.
  85. Loscher, W.; Wahnschaffe, U.; Mevissen, M.; Lerchl, A.; Stamm, A. Effects of weak alternating magnetic fields on nocturnal melatonin production and mammary carcinogenesis in rats. Oncology 1994, 51, 288-295.
  86. Meldrum, B. S.; Craggs, M. D.; Durmuller, N.; Smith, S. E.; Chapman, A. G. The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primates. Epilepsy Res. Suppl. 1992, 9, 307-311.
  87. Namba, T.; Morimoto, K.; Sato, K.; Yamada, N.; Kuroda, S. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 1994, 638, 36-44.
  88. Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Furuya, T.; Murase, K. 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)- quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1994, 37, 467-475.
  89. Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro- 2,3(1H,4H)-quinoxalinedione and related compounds. J. Med. Chem. 1996, 39, 3971-3979.
  90. Ohmori, J.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. Novel alpha-amino-3-hydroxy-5-methylisoxazole-4- propionate receptor antagonists: synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)- pyrido[2,3-b]pyrazinedione and related compounds. J. Med. Chem. 1996, 39, 1331-1338.
  91. Ohmori, J.; Shimizu-Sasamata, M.; Okada, M.; Sakamoto, S. 8- (1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1997, 40, 2053-2063.
  92. Steppuhn, K. G.; Turski, L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 1993, 265, 1063-1070.
  93. Turski, L.; Jacobsen, P.; Honore, T.; Stephens, D. N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
  94. J. Pharmacol. Exp. Ther. 1992, 260, 742-747.
  95. Yamaguchi, S.; Donevan, S. D.; Rogawski, M. A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993, 15, 179-184.
  96. Young, D.; Dragunow, M. Non-NMDA glutamate receptors are involved in the maintenance of status epilepticus. Neuroreport 1993, 5, 81-83.
  97. Young, D.; Dragunow, M. MK-801 and NBQX prevent electrically induced status epilepticus. Neuroreport 1994, 5, 1481-1484.
  98. Zarnowski, T.; Kleinrok, Z.; Turski, W. A.; Czuczwar, S. J. 2,3- dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993, 32, 895-900.
  99. Takano, Y.; Shiga, F.; Asano, J.; Ando, N.; Uchiki, H.; Anraku, T. Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxalinecarboxylic acid with a substituted phenyl group at the C-7 position. Bioorg. Med. Chem. Lett. 2003, 13, 3521-3525.
  100. Loscher, W.; Rundfeldt, C.; Honack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 1993, 5, 1545-1550.
  101. Zappala, M.; Gitto, R.; Bevacqua, F.; Quartarone, S.; Chimirri, A.; Rizzo, M.; De Sarro, G.; De Sarro, A. Synthesis and evaluation of pharmacological and pharmacokinetic properties of 11H- [1,2,4]triazolo[4,5-c][2,3]benzodiazepin-3(2H)-ones. J. Med. Chem. 2000, 43, 4834-4839.
  102. Grasso, S.; De Sarro, G.; De Sarro, A.; Micale, N.; Polimeni, S.; Zappala, M.; Puia, G.; Baraldi, M.; De Micheli, C. Synthesis and anticonvulsant activity of novel and potent 1-aryl-7,8- methylenedioxy-1,2,3,5-tetrahydro-4H-2,3-benzodiazepin-4-ones. Bioorg. Med. Chem. Lett. 2001, 11, 463-466.
  103. Ramakers, G. M.; Peeters, B. W.; Vossen, J. M.; Coenen, A. M. CNQX, a new non-NMDA receptor antagonist, reduces spike wave discharges in the WAG/Rij rat model of absence epilepsy. Epilepsy Res. 1991, 9, 127-131.
  104. Kaminski, R. M.; Van Rijn, C. M.; Turski, W. A.; Czuczwar, S. J.; Van Luijtelaar, G. AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. Eur. J. Pharmacol. 2001, 430, 251-259.
  105. Jakus, R.; Graf, M.; Ando, R. D.; Balogh, B.; Gacsalyi, I.; Levay, G.; Kantor, S.; Bagdy, G. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 2004, 1008, 236-244.
  106. Armstrong, D. D. The neuropathology of temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 1993, 52, 433-443.
  107. Ben-Ari, Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985, 14, 375-403.
  108. Du, F.; Whetsell, W. O., Jr.; Abou-Khalil, B.; Blumenkopf, B.; Lothman, E. W.; Schwarcz, R. Preferential neuronal loss in layer III of the entorhinal cortex in patients with temporal lobe epilepsy. Epilepsy Res. 1993, 16, 223-233.
  109. Hudson, L. P.; Munoz, D. G.; Miller, L.; McLachlan, R. S.; Girvin, J. P.; Blume, W. T. Amygdaloid sclerosis in temporal lobe epilepsy. Ann. Neurol. 1993, 33, 622-631.
  110. Wasterlain, C. G.; Fujikawa, D. G.; Penix, L.; Sankar, R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993, 34 Suppl. 1, S37-53.
  111. Saukkonen, A.; Kalviainen, R.; Partanen, K.; Vainio, P.; Riekkinen, P.; Pitkanen, A. Do seizures cause neuronal damage? A MRI study in newly diagnosed and chronic epilepsy. Neuroreport 1994, 6, 219-223.
  112. Lees, G. J.; Leong, W. The non-NMDA glutamate antagonist NBQX blocks the local hippocampal toxicity of kainic acid, but not the diffuse extrahippocampal damage. Neurosci. Lett. 1992, 143, 39-42.
  113. Lees, G. J.; Leong, W. Differential effects of NBQX on the distal and local toxicity of glutamate agonists administered intra- hippocampally. Brain Res. 1993, 628, 1-7.
  114. Lees, G. J.; Leong, W. Synergy between diazepam and NBQX in preventing neuronal death caused by non-NMDA agonists. Neuroreport 1994, 5, 2149-2152.
  115. Virgili, M.; Contestabile, A.; Barnabei, O. Simultaneous blockade of non-NMDA ionotropic receptors and NMDA receptor-associated ionophore partially protects hippocampal slices from protein synthesis impairment due to simulated ischemia. Hippocampus 1995, 5, 91-97.
  116. Penix, L. P.; Wasterlain, C. G. Selective protection of neuropeptide containing dentate hilar interneurons by non-NMDA receptor blockade in an animal model of status epilepticus. Brain Res. 1994, 644, 19-24.
  117. Chapman, A. G.; Elwes, R. D.; Millan, M. H.; Polkey, C. E.; Meldrum, B. S. Role of glutamate and aspartate in epileptogenesis; contribution of microdialysis studies in animal and man. Epilepsy Res. Suppl. 1996, 12, 239-246.
  118. Chapman, A. G. Glutamate receptors in epilepsy. Prog. Brain Res. 1998, 116, 371-383.
  119. de Lanerolle, N. C.; Eid, T.; von Campe, G.; Kovacs, I.; Spencer, D. D.; Brines, M. Glutamate receptor subunits GluR1 and GluR2/3 distribution shows reorganization in the human epileptogenic hippocampus. Eur. J. Neurosci. 1998, 10, 1687-1703.
  120. De Sarro, G.; Chimirri, A.; Meldrum, B. S. Group III mGlu receptor agonists potentiate the anticonvulsant effect of AMPA and NMDA receptor block. Eur. J. Pharmacol. 2002, 451, 55-61.